BioSpace News Archive

FDA

2022’s Top 5 FDA Drug Approvals are Major Advancements in Cancer, Cardiovascular Disease and Rare Disorders

The FDA’s top five approvals in 2022 represent an eclectic mix of cancer, cardiovascular and rare disease drugs.

December 22, 2022
·
4 min read
·
Editorial Staff
Drug Development

Lexicon’s AAK1 Inhibitor Disappoints in Phase II Postherpetic Neuralgia Study

Lexicon Pharmaceuticals’ LX9211 fell short of its primary efficacy endpoint, according to topline data from the Phase II RELIEF-PHN-1 study in post-herpetic neuralgia.

December 22, 2022
·
2 min read
·
Tristan Manalac
Business

BioSpace’s Top Biopharma M&A Candidates for 2023

Mergers and acquisitions are expected to be a key theme in the pharmaceutical industry in 2023.

December 22, 2022
·
7 min read
·
Heather McKenzie and George Budwell
I Peace, Inc. honored in BioSpectrum Asia Excellence Award 2022 with “Special Recognition in Cell Therapy”

I Peace, Inc. is a Palo Alto-based biotech company focusing on Nobel Prize-winning technology of induced pluripotent stem cells (iPSCs) and has successfully developed a novel system to mass manufacture clinical-grade iPSCs for cell therapy in a palm-sized closed cassette.

December 22, 2022
·
2 min read
Business

Merck Expands ADC Footprint with $9.3B Kelun Licensing Deal

Merck entered into a license and collaboration agreement with Chinese company Kelun-Biotech to develop seven antibody-drug conjugates candidates against oncology targets.

December 22, 2022
·
2 min read
·
Tristan Manalac
How a US Recession Could Affect Biopharma

U.S. recession will inevitably make many biopharma companies change course. However, it could cause some biotechs to change for the better.

December 22, 2022
·
5 min read
·
Christie Adams
Business

Eli Lilly Expands RNA Editing Collaboration with ProQR Therapeutics

Eli Lilly and ProQR Therapeutics expand their RNA-editing collaboration.

December 22, 2022
·
1 min read
·
Alex Keown
Policy

OKYO Pharma Announces U.S. FDA Clearance of IND Application for OK-101 for the Treatment of Dry Eye Disease

OKYO Pharma Limited announced that it has received clearance of its Investigational New Drug application from the U.S. Food and Drug Administration to initiate a Phase 2, first-in-human, clinical study of OK-101 for the treatment of DED.

December 22, 2022
·
5 min read
Genetown

PureTech Provides End of Year Report on Key Progress

PureTech Health plc, a clinical-stage biotherapeutics company dedicated to changing the treatment paradigm for devastating diseases, reported on the key progress made across its Wholly Owned Programs1 and Founded Entities2 in 2022.

December 22, 2022
·
19 min read
Pharm Country

New STIC trial data shows longer overall survival for therapy selection based on CELLSEARCH® CTC count in patients with metastatic breast cancer

Menarini Silicon Biosystems, a pioneer of liquid biopsy and single cell technologies, announced the promising long-term results of the STIC trial, on OS in patients with ER+/HER2- MBC.

December 22, 2022
·
5 min read